Analyst Articles

NVIDIA’s Revenue up 50%, Reaching a Record of $3.87B

Data Center and Gaming divisions drive strong revenue growth in FQ2/2021 and more than offset the decline in Automotive and Professional Visualization divisions’ results. Quarterly revenue was higher than the Company’s previous guidance and beat Analysts’ consensus estimate. [more]

Analyst Articles

XORTX Breaking Up the Code with Uric Acid

New 33-page Initiation Equity Research Report on XORTX, with a Speculative Buy rating and one-year price target of $2.30/share. The Company has two potential late stage drugs in development focused on kidney diseases that could initiate pivotal Phase 3 clinical trials in the next 12 months. [more]